PAM
HZNP

PSquared Asset Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

PSquared Asset Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-6,020
Closed -$144K – 20
2023
Q3 		$144K Buy
+6,020
New +$647K 0.01% 13
2023
Q2 		– Sell
-2,726
Closed -$450K – 19
2023
Q1 		$450K Sell
2,726
-5,074
-65% -$561K 0.06% 10
2022
Q4 		$117K Buy
+7,800
New +$648K 0.03% 11

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

PSquared Asset Management's HZNP Position: Q4 2023 in Review

PSquared Asset Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 2,001,749 shares — an estimated $232M sold.

PSquared Asset Management first reported a position in HZNP in Q4 2022 and held it in 4 quarters. The position peaked at $239M in Q1 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • PSquared Asset Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • PSquared Asset Management sold 2,001,749 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $232M.
  • PSquared Asset Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2022 and held it in 4 quarters.
  • PSquared Asset Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $239M in Q1 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on PSquared Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.